Judicial Panel on Multidistrict Litigation Issues Order on Zantac Products Liability Litigation (MDL No. 2924)
October 04, 2024
October 04, 2024
WASHINGTON, Oct. 4 -- The Judicial Panel on Multidistrict Litigation issued the following order (MDL No. 2924) on Oct. 3, 2024:
* * *
In Re: Zantac (Ranitidine) Products Liability Litigation
ORDER DENYING TRANSFER
Before the Panel:* Defendants GlaxoSmithKline plc and GlaxoSmithKline LLC (collectively, GSK) move under 28 U.S.C. Sec. 1407(c) to transfer the Eastern District of Pennsylvania Valisure action listed on Schedule A to the Southern Dist . . .
* * *
In Re: Zantac (Ranitidine) Products Liability Litigation
ORDER DENYING TRANSFER
Before the Panel:* Defendants GlaxoSmithKline plc and GlaxoSmithKline LLC (collectively, GSK) move under 28 U.S.C. Sec. 1407(c) to transfer the Eastern District of Pennsylvania Valisure action listed on Schedule A to the Southern Dist . . .